FDA Approves New Psoriasis Treatment for Adolescents
The FDA recently approved calcipotriene (Sorilux) foam 0.005% for the treatment of plaque psoriasis in patients aged 12 years and older.
Calcipotriene is a synthetic vitamin D3 analogue that is applied twice daily to the scalp and/or body.
YOU MIGHT LIKE
Active Ingredients in Sunscreen Exceed FDA Absorption Limits
FDA Approves Enbrel Biosimilar
The approval was based on data from two 8-week placebo-controlled trials that included patients with mild to moderate psoriasis on the body, as well as 8-week trial that included patients with moderate psoriasis on the scalp.
Application site erythema and pain were the most commonly reported adverse reactions. Patients with hypercalcemia should not receive calcipotriene.
FDA approves SORILUX(R) for adolescent plaque psoriasis [press release]. Adelaide, Australia. Mayne Pharma. https://www.prnewswire.com/news-releases/fda-approves-soriluxr-for-adolescent-plaque-psoriasis-300854930.html May 22, 2019. Accessed May 23, 2019.